

9466

8EHQ-0998-14258S



RECEIVED
OPPT NCIC

Amoco Corporation

Environment, Health and Safety 98 SEP -9 PM 12:36
28100 Torch Parkway, Suite 400
Warrenville Illinois 60555-4015
Product Stewardship and Toxicology

September 8, 1998

Sanitized Version

Document Processing Center (TS-790)
Attn: Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street, S.W.
Washington, D.C. 20460

COMPANY SANITIZED

Dear Sir or Madam:

This notice is being submitted on behalf of Amoco Oil Company, a wholly owned subsidiary of Amoco Corporation, in accordance with Section 8(e) of the Toxic Substance Control Act. Information included in this notice has been obtained from recent analytical chemical analyses of a grease thickened with a polyurea thickener

Chemical analysis of a polyurea-thickened grease has identified the presence of residual amounts of 4,4'-methylene dianiline (MDA) in the product. The concentration of MDA ranged from <200 ppm up to 8,200 ppm, representing a weight percent range of <0.02 to 0.82.

MDA is an unintentional byproduct produced during the manufacture of the grease thickener. Its presence in the grease was not previously known, so this analytical finding identifies a potential exposure to MDA that was also not previously known.

Amoco does not have, nor is it aware of any reports of adverse health effects attributable to the presence of MDA in the grease product. Although residual amounts of MDA are present in the grease, Amoco believes that the product is safe to use and that no substantial risk is posed. The reported adverse health effects linked to MDA exposure are associated with either high, chronic occupational exposures, or rodent bioassays using extremely high doses. Normal and customary uses of our grease product will not present similar levels of exposure to MDA.

Based on the analytical findings reported in this notice, Amoco is revising its MSDS and product labels accordingly.

RECEIVED
OPPT NCIC
98 SEP 16 AM 9:00

8EHQ-98-14258
88980000225S


Sanitized VersionConfidentiality Statement

This letter contains confidential business information (CBI). This claim of CBI is pursuant to § 14 of TSCA and to 40 CFR Part 2. All information claimed as confidential is boxed, and a sanitized version of this letter is provided. No public disclosure may be made of CBI contained and claimed in this letter absent prior notification to Amoco, pursuant to 40 CFR Part 2.

Response to the questions in the document entitled "Support Information for Confidentiality Claims" are given below:

If you have any questions, please contact me directly at (630) 836-5714.

Sincerely,



James D. Jernigan, Ph.D.
Director, Product Stewardship and Toxicology